To review some aspects of the relationship between epilepsy and depression that have recently received increasing attention and may become major research topics in the near future.
INTRODUCTION
The mutual relationships among epilepsy, seizures, and mood disorders have been recognized for a long time, fascinating generations of clinicians and neuroscientists [1] . In his famous quotations, Hippocrates stated that 'melancholics ordinarily become epileptics, and epileptics, melancholics: what determines the preference is the direction the malady takes; if it bears upon the body, epilepsy, if upon the intelligence, melancholy' [2] . Epilepsy is now recognized as a disorder of the brain characterized not only by an enduring predisposition to generate epileptic seizures, but explicitly also by the neurobiological, cognitive, psychological, and social consequences of this condition [3] . The new definition of epilepsy clearly highlights the importance of identifying and addressing behavioural problems of patients with epilepsy as these manifestations represent an integral part of the disease.
Mood disorders represent the most frequently encountered psychiatric comorbidities in patients with epilepsy [4] and are associated with poor quality of life [5] , seizure severity [6] , side effects of antiepileptic drugs (AEDs) [7] , drug resistance [8] , and a poor outcome after epilepsy surgery [9] . However, mood disorders are, more often than not, ignored, unless they are severe enough to cause major problems or disability. This is because of multiple factors, including the patients' reluctance to volunteer spontaneously information about mental health issues, a paucity (or total lack) of a specific training of the treating neurologist to recognize these psychiatric comorbidities and a lack of time in very busy clinics to screen for them. During last few years, clinicians became increasingly interested in psychiatric comorbidities of epilepsy, and screening instruments for mood [10] and anxiety disorders [11] are now available. In addition, epidemiological studies are now showing that some patients develop a complex neuropsychiatric condition characterized by depressive symptoms and recurrent seizures. This is a narrative review of some aspects of the relationship between epilepsy and depression that will probably receive increasing attention in the near future based on recent published data and new findings. Key references were identified through PubMed searches between 2011 and 2016 using the terms 'epilepsy' and 'depression'. Additional publications were hand searched if relevant for the discussion.
DEPRESSION AS A PREMORBID CONDITION
A number of studies are now suggesting that depression can be per se associated with an increased risk of epilepsy. Data from the General Practice Research Database show that the incidence rate ratio of depression is significantly higher in the 3 years preceding the onset of epilepsy [12] . A population-based study in Sweden shows that the ageadjusted odds ratio for the development of epilepsy is 2.5 for patients with a depressive disorder [13] . Three other population-based studies confirm that patients with a depressive disorder have a three to seven times increased risk to develop epilepsy [14] [15] [16] . A previous meta-analysis of Phase II and Phase III placebo-controlled trials of antidepressant drugs between 1985 and 2004 showed that study participants randomized to antidepressants other than clomipramine and bupropion are 69% less likely to develop seizures and patients randomized to placebo are 19 times more likely to have seizures as compared with the expected incidence in the general population [17] . All these evidences taken together clearly suggest that some patients with depression develop epilepsy as part of the 'natural course' of the depressive disorder or that depression may represent a premorbid phase of some epileptic syndromes.
In terms of neurobiological mechanisms, despite a large number of studies investigating the neurobiological links between epilepsy and depression, the clear basis for the development of epilepsy in patients with depressive disorders is not fully clarified. It is well known that depression and temporal lobe epilepsy share a disruption in the same brain networks but this is obviously not enough to explain the observed associations and, most importantly, the observed temporal sequences. Basic neuroscientists formulated a number of hypotheses mainly based on data from animal models. Low serotonin levels have been historically described in mood disorders but it seems now evident that they are present in epilepsy as well. In fact, similar findings are reported in animal models of epilepsy such as genetically epilepsy-prone rats [18] , pilocarpine status epilepticus model in Wistar rats [19] and Rhesus monkeys [20] . It is still unclear whether there is a specific threshold in serotonin loss leading from depression to spontaneous seizures and which serotoninergic pathway is more likely to be responsible for this transition. Interestingly, a deletion of the 5HTC2 receptor subunit lowers the threshold for audiogenic seizures in mouse models of epilepsy [21] but further studies are needed.
Another coming area of research looking at the biological mechanisms shared by epilepsy and depression is that of stress. In reality, this is not entirely new as the role of the hypothalamicpituitary-adrenal axis in depression is well established. However, it is now evident that pretreatment with corticosterone accelerates the kindling process in rats [22] and this would be in keeping with the emerging literature on the potential role of stress in epilepsy [23 && ] not only as a precipitant factor but also as a potential causative one [24] . The disruption in GABA and glutamate neurotransmissions used to be a classic finding in epilepsy but cumulative data are now showing similar findings in depression through a hypothalamic-pituitary-adrenal-mediated mechanism. In fact, steroids can modulate the expression and composition of GABA-A receptors promoting epileptogenesis and increasing brain excitability in general [25, 26] . As a result, GABA hypofunction is now also reported in patients with depression [27] and NMDA receptor antagonists are now tested not only as antiepileptic agents but also as antidepressants [28] .
Advances in the neurobiology and molecular pharmacology of the relationship between depression and epilepsy are bringing into the epilepsy field
KEY POINTS
Epidemiological studies suggest that depression may represent a premorbid phase in some patients with epilepsy.
Double stigma probably represents a relevant barrier to diagnosis and treatment of mood disorders in epilepsy but no data are available.
Up to 13% of children with epilepsy suffer from depression but this seems to be more common in those with lower IQ, language delays or decreasing scores on neuropsychological assessment.
Suicide represents 11.5% of all causes of death in epilepsy, being three times more frequent than in the general population.
neurochemical pathways, such as serotonin and melatonin, traditionally investigated for mood disorders, and completely new biological targets such as galanin receptors [29] . Nalutozan is a selective 5HT1A agonist currently under investigation for both anxiety and epilepsy, whereas beprodone is a melatonin type 3 receptor agonist under Phase IIb development in drug refractory localization-related epilepsies [29] . Galanin is one of the most inducible neuropeptides and its biosynthesis is increased 2-10-fold upon seizure activity in the brain. Agonists of galanin receptor type 2 seem to have both anticonvulsant and analgesic/anxiolytic properties and a specific agonist (Nax 810-2) [4] is currently under preclinical investigation.
DEPRESSION AND ANXIETY IN CHILDREN
Depression has been historically studied and investigated in the context of adult epilepsies. However, in the general population, anxiety disorders are much more common in children than in adults [30, 31] . Diagnosis and management of mood and anxiety disorders in children have important implications. In fact, children with anxiety disorders seem to be at increased risk of further psychiatric comorbidities such as attention deficit hyperactivity disorder (ADHD) or conduct disorder [32] . In addition, half of adults with depression had a history of anxiety before the age of 15 [33] . For all these reasons, the American Academy of Child and Adolescent Psychiatry has recommended that children and adolescents are routinely screened for symptoms of anxiety [34] . It seems, thus, evident that both a careful assessment and a prompt treatment of depression and anxiety in children with epilepsy would prevent the development of major psychiatric disorders during adulthood.
Epidemiological studies of depression in children with epilepsy are still limited compared with the large number of publications in adults. A longterm prospective study in newly diagnosed children with epilepsy followed up for up to 9 years reported a 13% prevalence of depression [35] . A large US nationwide survey found depression in 8% of children with current epilepsy, 7% of children with a previous history of seizures, and 2% of controls [36] and similar figures were reported by a UK community-based study of children with epilepsy 5-15 years of age attending schools in Sussex [37] . Anxiety and depression seem to be more common in children with epilepsy and lower intelligence quotient (IQ), language delays, or decreasing scores on neuropsychological assessment [38] [39] [40] . As already mentioned, children with anxiety are at increased risk of ADHD and it is now established that this is two to three times more frequent in epilepsy as compared to the general population [41] . In addition, a community-based survey in more than 1000 adult patients with epilepsy reported that ADHD-like symptoms are present in one out of five study participants and are associated with depression, anxiety, drug resistance, and poor quality of life [42] . The importance of ADHD should not be underestimated as it is a well known risk factor for major psychiatric problems during adulthood such as alcohol and substance abuse, psychiatric hospitalizations, and antisocial personality disorder [43] . All these evidences taken together suggest that some children with epilepsy can develop a complex neuropsychiatric condition characterized by mood and anxiety as well as cognitive and neurodevelopmental problems and this seems to be evident in children with even subtle neurological signs or cognitive problems. In fact, neurotypical (normal neurologic, cognitive, and imaging examinations) young adults with childhood-onset epilepsy do not present increased rates of psychiatric disorders [44] .
But the relationship between depression and epilepsy in children is even more complex than that as many psychological factors are implicated as compared with adults. Dunn et al. [45] found that the adolescent attitude toward the epilepsy and an external or unknown locus of control were predictors of depression. The adverse effect of seizures on the family, limited emotional support, poor communication, inadequate support of child autonomy, and maternal depression contribute to anxiety and depression in the child with epilepsy [45] [46] [47] . It is, therefore, evident that, apart from neurobiological variables, social variables, stigma, and parental attitudes play a relevant role in mood and anxiety disorders in children with epilepsy. For all these reasons, tailored treatment approaches are needed and should include multidisciplinary approaches, including psychotherapy, occupational, and vocational therapy. In addition, the role of perceived stigma will receive increasing attention in prevention and management of mood disorders in children with epilepsy.
REDUCING MORTALITY OF EPILEPSY: SUICIDE PREVENTION
Although suicide represents 1% of all deaths in the general population, it accounts for 11.5% of all deaths in epilepsy. These figures are not so different from those of Sudden Unexpected Death in Epilepsy (SUDEP) that accounts for 18% of all deaths in epilepsy. However, as compared with SUDEP, suicide is still an unmentionable issue in epilepsy. Standard mortality ratio for suicide in patients with epilepsy is three times higher than the general population [48] and such a risk remains high even after excluding those with a history of psychiatric disorders and adjusting for socioeconomic factors [49] . A population-based study in England has shown that 25% of patients with epilepsy have a lifetime history of suicidal thoughts and more than 10% have a lifetime history of suicidal attempts [50] . Similar figures have been reported by another population-based study from Canada [51] . Several studies have attempted to identify reasons for such an increased risk. Historically, suicide has been linked to temporal lobe epilepsy [52] but more recent data failed to find such a close association [53] . Severity of the seizure disorder does not seem to be a relevant factor [54] whereas depression is, at present, the major risk factor [55, 56] . It is likely that other, still unknown, biological factors contribute to the increased risk of suicide in epilepsy [57] given the bidirectional relationship between epilepsy and depression [12, 16] . In fact, a recent study identified an association between suicide attempts and epilepsy even before the onset of seizures themselves, and independently of psychiatric disorders [58 && ]. As already mentioned, suicide in epilepsy has long represented, and probably still represents, a taboo. In fact, if we analyse the whole literature on suicide in epilepsy, 50% of currently available indexed studies have been published in the last 10 years, whereas the remaining 50% in the preceding 30-40 years [59] . The interest on suicide in epilepsy rapidly escalated during last few years and the US Food and Drug Administration (FDA) alert on the increased risk of suicidal ideation and behaviour in people taking AEDs has probably contributed to that [60] . The FDA meta-analysis focused on multicentre randomized placebo-controlled trials of 11 AEDs. Spontaneously reported suicidality occurring during double-blind trials with an AED (or within 1 day of stopping) were sought and categorized. Results suggested an increased suicidality risk in patients taking AEDs. The FDA results were received with great scepticism by clinicians and professional societies [61] . Some investigators questioned the validity of FDA findings, identifying serious methodological flaws [62] . However, there is no doubt that the FDA document has finally highlighted the issue of suicide in epilepsy. An expert consensus statement developed by an ad hoc task force of the Commission on Neuropsychobiology of the International League Against Epilepsy (ILAE) stressed the need for screening instruments of suicide and clinical monitoring during clinical trials of AEDs [63] .
Prevention is the only treatment for suicide but research on screening for suicide in epilepsy is still at a very early stage. The Columbia Suicide Severity Rating Scale (CSSRS) [64] is currently recommended to identify and monitor patients at high suicidality risk in clinical trials of AEDs [63] . It is available in several languages, and a validity study in epilepsy was published [65] . However, it is rather unrealistic to consider the CSSRS as a user-friendly clinical instrument to use in routine clinical practice for screening purposes. A cross-sectional study compared the CSSRS, administered either in-person or using an interactive voice response system (E-CSSRS) against the MINI, and showed good to excellent psychometric properties [65] . However, both the E-CSSRS and the MINI are time consuming and have to be administered by a trained health professional, becoming not cost-effective. Other authors suggested the use of item 9 of the Beck Depression Inventory [56] but the validity and psychometric properties of this method have never been investigated. The Neurological Disorders Depression Inventory for Epilepsy (NDDIE) was developed for the rapid and objective detection of a major depressive episode in patients with epilepsy [10] . It has shown to be a very practical and userfriendly screening instrument in any outpatient or inpatient setting. The NDDIE is now available in a number of languages and many clinicians are becoming increasingly familiar with this screening tool in their clinical practice. A recent study validated the use of item 4 of the NDDIE as a suicidality screening instrument, showing good psychometric properties [66] . Suicide may be considered an unmentionable issue by many neurologists, as they may feel uncomfortable in asking the patient directly. However, according to the NICE guidelines, suicidal ideation and intent should always be part of the assessment of depression. The NDDIE as a rapid suicidality-screening instrument represents an easy and straightforward way to introduce the issue of suicide in a busy epilepsy clinic, by simply asking the patient why he or she has answered in that way item 4, and whether he or she already has a plan. This will also stimulate epilepsy centres to develop shared care pathways with liaison psychiatric services to assess whether the person has adequate social support and is aware of sources of help; to arrange help appropriate to the level of risk; and to advise the person to seek further help if the situation deteriorates. In fact, it is important to bear in mind that, aside from the already mentioned barriers, reporting suicide ideation or behaviours may be affected by complex and often conflicting cultural attitudes [67] . In May 2013, the 66th World Health Assembly adopted the first-ever Mental Health Action Plan of the WHO of which suicide prevention is an integral part, with the goal of reducing the rate of suicide in countries by 10% by 2020 [68] . The www.co-neurology.comepilepsy community should not lose this opportunity and should support the dialog between neurology and psychiatry services in the development of effective suicide prevention strategies to reduce mortality of patients with epilepsy.
DOUBLE STIGMA IN EPILEPSY: THE NEW CHALLENGE
The increasing attention to psychiatric comorbidities of epilepsy is bringing to light the issue of double stigma. In fact, the stigma associated with mental health problems combined to that of epilepsy probably represents a major barrier to prevention and treatment of depression and suicide in epilepsy, especially in some geographic areas. Interestingly enough, no studies investigated the issue of double stigma in epilepsy even if it is well known in other medical conditions, for example, obesity and mental health [69] or HIV and mental health [70] .
Stigma toward epilepsy is present in both highincome and poor resources countries [71] and plays a role in mood and anxiety problems in both people with epilepsy and their caregivers [72] . In low and middle income countries, 20% of mothers of children with epilepsy feel stigmatized because of their child's neurological condition [73] and the caregiver's perception of burden, together with the level of family functioning, are indirectly correlated with depressive symptoms in people with epilepsy via the mediating effect of caregiver depression [74] . In high-income countries, social aspects of stigma are also important determinants of anxiety and depression in epilepsy [75] . In fact, stigma can affect the more intimate life domains of people such as cohabitation and marriage. Patients with epilepsy are less likely to be married and patients suffering from the enacted stigma are significantly more likely to get divorced in comparison with people with other chronic medical conditions [76] [77] [78] . The US Centers for Disease Control and Prevention Epilepsy Program indicated that, in the US, one in five patients with epilepsy lives alone and less than one in four lives in households with two adults and children [79] . Adults with epilepsy living alone may be at increased risk of injury associated with uncontrolled seizures, mood disorders, and mental health issues associated with social isolation and early mortality because of SUDEP or suicide.
Persistent stigma around mental health issues is one of the key barriers to the treatment of depression, especially in ethnic minorities [80] . For example, data from the Sequenced Treatment Alternatives to Relieve Depression (STAR Ã D) trial show that, in the US, Hispanics initiate antidepressant medication treatment at a much lower rate than whites, and are more likely to discontinue their treatment without consulting their physician [81] . In the general population, common concerns about depression treatments include fears about the addictive and harmful properties of antidepressants, worries about taking too many pills, and the stigma attached to taking psychotropic medications. It is easy to figure out the impact of these concerns in patients with epilepsy with, in addition, the general belief that antidepressant can potentially lower the seizure threshold.
The double stigma associated with epilepsy and mental health problems clearly has a negative impact on prevention and care efforts. It creates a context in which patients are reluctant to acknowledge mental health issues, and has strong psychological consequences for those who have uncontrolled epilepsy, increasing social isolation, and depression. Addressing stigma and discrimination in healthcare systems and the wider community should be an essential part of epilepsy care [82 & ]. In poor resource countries, stigma directly affects access to healthcare [83, 84] but living in a high-income country with better health system performance and higher health expenditure per capita does not necessarily lead to a reduction in perceived discrimination, unless the public health system invests in awareness programmes to increase public knowledge and reduce stigma [85] . Depressive symptoms and poor social supports have the greatest impact on reported felt stigma in people with epilepsy [86] . It is evident that any program dedicated to the prevention and treatment of psychiatric problems in epilepsy has to consider stigma and related factors. People living with epilepsy should be centrally involved in policy formation and service delivery. Their involvement in the planning and delivery of mental health support will similarly contribute to the development of relevant services, including peer-led initiatives, and can empower them by building self-esteem, decreasing isolation, and enabling openness about epilepsy and mental health issues. Patients can be involved in a number of ways, including policymaking and strategic planning, formation of support groups, counselling programs, positive living courses, and inclusion in the training of mental health professionals. Double stigma means double challenge and for this reason it becomes even more important to invest energies and resources. Further robust data collection and surveillance to identify points of intervention are urgently needed.
CONCLUSION
It is now recognized that patients with epilepsy may present with a complex neuropsychiatric syndrome accompanied by depression and purpose-developed screening instruments are now available. However, data on prevention and early diagnosis are still lacking. Data on children will be of great value for the development of clinical pathways for early diagnosis of depression and suicide prevention. In fact, further studies on suicide will be of great value in order to reduce mortality in epilepsy. Suicide prevention has finally become the goal of a new WHO strategy and this is an important opportunity to further implement the management of patients at high risk such as people with epilepsy. Overcoming stigma and fighting against the double stigma of epilepsy and mental disorders will be the new challenge.
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